Ahmed A. K. Hasan

TL;DR: Among patients with stable atherosclerosis, low‐dose methotrexate did not reduce levels of interleukin‐1β, interleUKin‐6, or C‐reactive protein and did not result in fewer cardiovascular events than placebo and was associated with elevations in liver‐enzyme levels, reductions in leukocyte counts and hematocrit levels, and a higher incidence of non–basal‐cell skin cancers than placebo.

TL;DR: In this article, phase change materials (PCMs) were used to regulate the temperature of building integrated photovoltaics (BIPV) using phase change material (PCM).

TL;DR: If low-dose methotrexate reduces cardiovascular events, CIRT would provide a novel therapeutic approach for the secondary prevention of heart attack, stroke, and cardiovascular death.

TL;DR: Inflammatory and immune mechanisms can link traditional and emerging risk factors to atherosclerosis, and offer novel avenues for therapeutic intervention.

TL;DR: Genotype-guided selection of an oral P2Y12 inhibitor, compared with conventional clopidogrel therapy without point-of-care genotyping, resulted in no statistically significant difference in a composite end point of cardiovascular death, myocardial infarction, stroke, stent thrombosis, and severe recurrent ischemia.